Physician profile
Joseph Gelbfish
NPI 1417058165
$3,513.02
in general payments reported to CMS, 2019-2025
22 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $524 · 2021: $573 · 2022: $562 · 2023: $471 · 2024: $415 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,081.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $665.31 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $617.84 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $442.48 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $316.10 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $291.67 | 2019-2025 | |
| Edwards Lifesciences Corporation | $180.96 | 2019-2023 | Sapien 3 Ultra Resilia |
| Amarin Pharma, INC. | $153.62 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $130.72 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2024 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $104.51 | 2020-2022 | |
| Amgen INC. | $88.82 | 2019-2024 | Repatha |
| Medtronic, INC. | $81.58 | 2022-2024 | Corevalve Evolut R |
| Merck Sharp & Dohme LLC | $72.77 | 2023 | Verquvo |
| Sanofi Pasteur INC. | $59.26 | 2020-2022 | |
| Biotronik INC. | $27.14 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $25.40 | 2019 | |
| Genentech USA, INC. | $23.33 | 2019 | |
| Bard Peripheral Vascular, INC. | $22.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.41 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $21.73 | 2019 | |
| Medtronic Vascular, INC. | $21.48 | 2019 | |
| Boston Scientific Corporation | $17.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gelbfish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.